Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to three new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) totaling 8,400 shares of common stock.
The RSUs will vest in three equal installments on April 1 of 2026, 2027, and 2028, contingent upon continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), un'azienda in fase clinica specializzata in terapie basate su CRISPR, ha concesso premi di incentivazione a tre nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2024. I premi consistono in unità azionarie vincolate nel tempo (RSU) per un totale di 8.400 azioni ordinarie.
Le RSU matureranno in tre rate uguali il 1° aprile del 2026, 2027 e 2028, a condizione di un impiego continuato. Questi premi, approvati dal comitato per la compensazione di Intellia, sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti della società, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), una empresa de edición genética en etapa clínica especializada en terapias basadas en CRISPR, ha otorgado premios de incentivo a tres nuevos empleados bajo su Plan de Incentivo 2024. Los premios consisten en unidades de acciones restringidas basadas en tiempo (RSUs) que totalizan 8,400 acciones ordinarias.
Las RSUs se consolidarán en tres cuotas iguales el 1 de abril de 2026, 2027 y 2028, condicionadas a la continuidad del empleo. Estos premios, aprobados por el comité de compensación de Intellia, se otorgaron fuera de los planes de incentivos de acciones aprobados por los accionistas de la empresa, de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
인텔리아 테라퓨틱스 (NASDAQ:NTLA), CRISPR 기반 치료에 특화된 임상 단계 유전자 편집 회사가 2024년 유인 계획에 따라 세 명의 신규 직원에게 유인 보상을 부여했습니다. 보상은 총 8,400주에 해당하는 시간 기반 제한 주식 단위(RSU)로 구성됩니다.
RSU는 2026년, 2027년, 2028년 4월 1일에 세 번의 동일한 할부로 분할되어 부여되며, 지속적인 고용 조건이 있습니다. 이러한 보상은 인텔리아의 보상 위원회에서 승인되었으며, 나스닥 상장 규칙 5635(c)(4)에 따라 회사의 주주 승인 자본 인센티브 계획 외부에서 부여되었습니다.
Intellia Therapeutics (NASDAQ:NTLA), une entreprise de thérapie génique en phase clinique spécialisée dans les thérapies basées sur CRISPR, a accordé des primes d'incitation à trois nouveaux employés dans le cadre de son Plan d'Incitation 2024. Les primes consistent en des unités d'actions restreintes basées sur le temps (RSU) totalisant 8 400 actions ordinaires.
Les RSU seront acquises en trois versements égaux le 1er avril 2026, 2027 et 2028, sous réserve d'un emploi continu. Ces prix, approuvés par le comité de rémunération d'Intellia, ont été accordés en dehors des plans d'incitation en actions approuvés par les actionnaires de l'entreprise, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), ein Unternehmen für genetische Bearbeitung in der klinischen Phase, das sich auf CRISPR-basierte Therapien spezialisiert hat, hat drei neuen Mitarbeitern im Rahmen seines Anreizplans 2024 Anreizpreise gewährt. Die Preise bestehen aus zeitlich begrenzten Aktienanteilen (RSUs) mit insgesamt 8.400 Stammaktien.
Die RSUs werden in drei gleichen Raten am 1. April 2026, 2027 und 2028 fällig, abhängig von einer fortgesetzten Anstellung. Diese Preise, die vom Vergütungsausschuss von Intellia genehmigt wurden, wurden außerhalb der von den Aktionären genehmigten Eigenkapitalanreizpläne des Unternehmens gemäß der Nasdaq-Börsenregel 5635(c)(4) gewährt.
- None.
- None.
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded an inducement grant to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 8,400 shares of Intellia’s common stock, with one-third of such RSUs vesting on April 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
How many shares were granted in Intellia Therapeutics (NTLA) latest inducement awards?
What is the vesting schedule for NTLA's April 2025 inducement grants?
Under which plan were NTLA's April 2025 inducement grants awarded?
What is the purpose of NTLA's inducement grants announced in April 2025?
